Respiratory infections like COVID-19 and influenza are caused when pathogens like SARS-CoV-2 and influenza virus enter the body through the mucous membranes in the nose and throat.
In preventing these respiratory infections, prevention of virus infection itself at the mucosal surface of the nose and throat consider to be very important. Intranasal vaccines, designed to induce effective immunity at these mucosal sites, are therefore gaining traction.
Nasal vaccines have the advantage of reducing anxiety about injections and reducing the burden on medical staff, but there are still many issues that need to be overcome, such as the method of spraying and adjusting the dose administered into the nasal cavity. In collaboration with Chiba University Hospital, SHIONOGI has founded the "Division for Human Mucosal Vaccine Research"* to address these issues and advance the development of effective intranasal vaccines from both clinical and non-clinical aspects. We're also exploring the development of oral vaccines for easier administration in the future.
Schematic diagram of nasal vaccine

* Shionogi Announces the Conclusion of a Contract for the Establishment of a Research

Department for Mucosal Vaccines with Chiba University Hospital. (Press Release, February 10, 2022)